{rfName}
Lo

Indexed in

License and use

Altmetrics

Grant support

Declaration of personal interests: EG, EM, MB, MAS, FJ, RMM, JA, AO, MHG, ML and AC: Received fees for consultation and remunerate speeches from Intercept Pharma; CFR: His institution has received grant support from Intercept Pharma-Advanz. JLM, MLGB, MC, IC, JF, PCM, GM, IG, IO, SRT, JP, ER, ShGP, DEG, JMS, DG, LS, LA, AS, JU, MLG and EP-F: Have nothing to disclose.

Analysis of institutional authors

Gutierrez, M LAuthorFernandez-Rodriguez, C MCorresponding Author
Share
Publications
>
Article

Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

Publicated to:Alimentary Pharmacology & Therapeutics. 59 (12): 1604-1615 - 2024-05-01 59(12), DOI: 10.1111/apt.18004

Authors: Gomez, E; Montero, J L; Molina, E; Garcia-Buey, L; Casado, M; Fuentes, J; Simon, M A; Diaz-Gonzalez, A; Jorquera, F; Morillas, R M; Presa, J; Berenguer, M; Conde, M I; Olveira, A; Macedo, G; Garrido, I; Hernandez-Guerra, M; Olivas, I; Rodriguez-Taje, S; Londono, M; Sousa, J M; Ampuero, J; Romero-Gonzalez, E; Gonzalez-Padilla, Sh; Escudero-Garcia, D; Carvalho, A; Santos, A; Gutierrez, M L; Perez-Fernandez, E; Aburruza, L; Uriz, J; Gomes, D; Santos, L; Martinez-Gonzalez, J; Albillos, A; Fernandez-Rodriguez, C M

Affiliations

CHU Coimbra, Dept Gastrenterol, Coimbra, Portugal - Author
CHU Sao Joao CHUSJ, Serv Gastrenterol, Porto, Portugal - Author
Complejo Hosp Leon, Leon, Spain - Author
Complejo Hosp Navarra, Pamplona, Spain - Author
Complexo Hosp Univ Santiago, Coruna, Spain - Author
Ctr Hosp & Univ Coimbra, Coimbra, Portugal - Author
Ctr Hosp Tras Os Montes Alto Douro, Vila Real, Portugal - Author
Hosp Badalona Germans Trias & Pujol, Badalona, Spain - Author
Hosp Clin Barcelona, Barcelona, Spain - Author
Hosp Clin Univ Lozano Blesa, Zaragoza, Spain - Author
Hosp Univ 12 Octubre, Madrid, Spain - Author
Hosp Univ Canarias, Santa Cruz De Tenerife, Spain - Author
Hosp Univ Donostia, Donostia San Sebastian, Spain - Author
Hosp Univ Fdn Alcorcon, Madrid, Spain - Author
Hosp Univ La Fe, Valencia, Spain - Author
Hosp Univ La Paz, Madrid, Spain - Author
Hosp Univ La Princesa, Madrid, Spain - Author
Hosp Univ Marques Valdecilla, Santander, Spain - Author
Hosp Univ Miguel Servet, Zaragoza, Spain - Author
Hosp Univ Ramon & Cajal, Madrid, Spain - Author
Hosp Univ Reina Sofia, Cordoba, Spain - Author
Hosp Univ Torrecardenas, Almeria, Spain - Author
Hosp Univ Virgen Rocio, Seville, Spain - Author
Inst Biomed Sevilla IBIS, Seville, Spain - Author
Ramon & Cajal Inst Hlth Res, Madrid, Spain - Author
Univ Alcala de Henares, Alcala De Henares, Spain - Author
Univ Rey Juan Carlos, Hosp Univ Fdn Alcorcon, Madrid, Spain - Author
Univ Rey Juan Carlos, Madrid, Spain - Author
Univ Valencia, Hosp Clin Univ Valencia, Valencia, Spain - Author
Univ Valencia, Valencia, Spain - Author
Univ Zaragoza, Zaragoza, Spain - Author
See more

Abstract

Background: Suboptimal response to ursodeoxycholic acid occurs in 40% of primary biliary cholangitis (PBC) patients, affecting survival. Achieving a deep response (normalisation of alkaline phosphatase [ALP] and bilirubin

Keywords
AdultAgedAlkaline phosphataseBezafibrateBilirubinBiochemical responseChenodeoxycholic acidCholagogues and cholereticsCirrhosisDrug therapy, combinationFemaleFibric acidsHumansLiver cirrhosis, biliaryLongitudinal studiesMaleMiddle agedObeticholic acidPlacebo-controlled trialSpainSurvivalTreatment outcomeUrsodeoxycholic acid

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Alimentary Pharmacology & Therapeutics due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 18/143, thus managing to position itself as a Q1 (Primer Cuartil), in the category Gastroenterology & Hepatology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-05-17:

  • WoS: 3
  • Scopus: 5
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-17:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 16.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 16 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 10.05.
  • The number of mentions on the social network X (formerly Twitter): 17 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Portugal.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (Fernández Rodríguez, Conrado Manuel).

the author responsible for correspondence tasks has been Fernández Rodríguez, Conrado Manuel.